| Chemotherapy in alveolar soft part sarcomas. What do we know? |
| |
| 引用本文： | Reichardt P,Lindner T,Pink D,Thuss-Patience PC,Kretzschmar A,Dörken B. Chemotherapy in alveolar soft part sarcomas. What do we know?[J]. European journal of cancer (Oxford, England : 1990), 2003, 39(11): 1511-1516. DOI: 10.1016/S0959-8049(03)00264-8 |
| |
| 作者姓名： | Reichardt P Lindner T Pink D Thuss-Patience PC Kretzschmar A Dörken B |
| |
| 摘 要： |
|
| 收稿时间： | 2003-02-17 |
Chemotherapy in alveolar soft part sarcomas: What do we know? |
| |
| Reichardt P,Lindner T,Pink D,Thuss-Patience P C,Kretzschmar A,Dörken B. Chemotherapy in alveolar soft part sarcomas: What do we know?[J]. European journal of cancer (Oxford, England : 1990), 2003, 39(11): 1511-1516. DOI: 10.1016/S0959-8049(03)00264-8 |
| |
| Authors: | Reichardt P Lindner T Pink D Thuss-Patience P C Kretzschmar A Dörken B |
| |
| Affiliation: | 1. Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong Province, China;2. Cancer Research Institute, Southern Medical University, Guangzhou 510515, Guangdong Province, China;1. Department of Anesthesia, China-Japan Union Hospital of Jilin University, Changchun, China;2. Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA;3. Department of Respiratory Care Services, Massachusetts General Hospital, Boston, Massachusetts, USA;4. Department of Anesthesia, the First Affiliated Hospital of Harbin Medical University, Harbin, China;5. Department of Emergency and Disaster Medicine, Tokushima University Hospital, Tokushima, Japan;6. Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA;1. Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, People''s Republic of China;2. Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, People''s Republic of China;3. China National Clinical Research Center for Neurological Diseases, Beijing, People''s Republic of China;1. Hematology Department, Transplantation Program, Institut Paoli Calmettes, Marseille, France;2. Aix-Marseille Université, Marseille, France;3. Inserm UMR 1068/Centre de Recherche en Cancérologie de Marseille, Marseille, France;4. Humanitas Cancer Center, Hematology Unit, Instituto Clinico Humanitas, Rozzano, Milano, Italy;5. Cell Therapy Facility, Institut Paoli Calmettes, Marseille, France;1. National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), 31 Kashirskoe shosse, 115409 Moscow, Russian Federation;2. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, 24 Kashirskoe shosse, 115201 Moscow, Russian Federation;3. Laboratoire de Recherche en Nanosciences, LRN - EA4682, Université de Reims Champagne-Ardenne, 51 rue Cognacq Jay, 51100 Reims, France |
| |
| Abstract: | Alveolar soft part sarcoma (ASPS) is a rare tumour. Published series about treatment and outcome are scarce. Conclusive data about the response to chemotherapy are not available. The aim of this study was to analyse the efficacy of palliative chemotherapeutic treatment options and the incidence and mode of presentation of brain metastases. We retrospectively analysed our own sarcoma data-base and reviewed the literature. From our registry containing 757 patients, we identified 8 patients with ASPS. From the literature, 47 cases of adult patients and 13 children with sufficient data about chemotherapy were identified. Response to first-line chemotherapy in 68 patients was: complete remission (CR) 4%, partial remission (PR) 3%, stable disease (SD) 41%, progressive disease (PD) 51%. 285 patients with stage IV disease were evaluable for the analysis of metastatic sites. The incidence of brain metastases was 30.5% (87/285). Brain metastases were detected at a median interval of 48 months (range 0-396 months) after the primary diagnosis. Median survival after the diagnosis of brain metastases was 12 months. The median survival for patients with stage IV disease treated by chemotherapy was 36+ months (range 10-132 months) (31 patients evaluable) with a median follow-up of 46 months (range 10-135 months). ASPS shows a high incidence of brain metastases, at least 3 times higher than that of other soft tissue sarcomas. Chemotherapeutic regimens used for the treatment of other soft tissue sarcomas lack efficacy in ASPS. Staging investigations for ASPS should routinely include imaging of the brain. ASPS patients should not be treated with chemotherapy outside of controlled clinical trials. New targets for specific biologically-directed therapies need to be developed. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect PubMed 等数据库收录！ |
|
